Understanding how DNA repair affects cancer treatment with alpha particles
Official title: Radiobioeffect Modeling of αRPT
Funded at Johns Hopkins University · NIH-10931454 · Data updated 2026-11-12
This study is looking at how well prostate cancer cells can fix their damaged DNA and how that affects the success of a specific type of radiation therapy that uses alpha particles, aiming to help doctors better plan treatments and improve results for patients already receiving this therapy.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $423,590 |
| NIH project number | 5P01CA272222-02 |
| Project ID | NIH-10931454 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are prostate cancer patients undergoing treatment with alpha particle therapies, particularly those with known deficiencies in DNA repair mechanisms.
✕Less likely to help
Patients with cancers other than prostate cancer or those not receiving αRPT may not benefit from this research.
What this research studies
This research investigates how the ability of cancer cells to repair DNA damage influences the effectiveness of alpha particle emitter radiopharmaceutical therapy (αRPT) in treating prostate cancer. By estimating the absorbed doses of radiation in tissues and evaluating the status of DNA double-strand break repair, the study aims to improve predictions of treatment outcomes. The research combines preclinical and clinical approaches to rigorously assess the relationship between radiation dose and cancer response, focusing on patients already receiving an FDA-approved αRPT treatment. The goal is to enhance treatment planning and patient outcomes through a better understanding of DNA repair mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments by optimizing radiation therapy based on individual DNA repair capabilities.
How similar studies have gone: Previous research has shown promising results in using DNA repair status to predict treatment outcomes in cancer therapies, suggesting that this approach could be effective.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Sgouros, George — Johns Hopkins University
- Study coordinator: Sgouros, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.